Similar articles for PMID: 23528600

Year	Number of Results
1998	2
2001	1
2004	1
2005	1
2006	2
2008	1
2009	3
2010	7
2011	22
2012	26
2013	23
2014	30
2015	8
2016	6
2017	3
2018	7
2019	1
2020	2
2024	0

1

[Rare case of no effective therapy with natalizumab (tisabri) in a female patient with multiple sclerosis and neutralizing antibodies to the drug].

Iakushina TI, Eliseev IuV, Kotov SV. Iakushina TI, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(2 Pt 2):83-6. Zh Nevrol Psikhiatr Im S S Korsakova. 2013. PMID: 23528600 Russian. No abstract available.

2

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.

Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J. Vennegoor A, et al. Mult Scler. 2013 Apr;19(5):593-600. doi: 10.1177/1352458512460604. Epub 2012 Sep 19. Mult Scler. 2013. PMID: 22992450

3

Natalizumab therapy for highly active pediatric multiple sclerosis.

Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, Hellwig K, Pitarokoili K, Storm van's Gravesande K, Karenfort M, Blaschek A, Meyer A, Seidl R, Debelic D, Vass K, Prayer D, Kristoferitsch W, Bayas A. Kornek B, et al. JAMA Neurol. 2013 Apr;70(4):469-75. doi: 10.1001/jamaneurol.2013.923. JAMA Neurol. 2013. PMID: 23420110

4

Characterization of anti-natalizumab antibodies in multiple sclerosis patients.

Lundkvist M, Engdahl E, Holmén C, Movérare R, Olsson T, Hillert J, Fogdell-Hahn A. Lundkvist M, et al. Mult Scler. 2013 May;19(6):757-64. doi: 10.1177/1352458512462920. Epub 2012 Oct 8. Mult Scler. 2013. PMID: 23045379

5

Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis.

Prosperini L, De Angelis F, De Angelis R, Fanelli F, Pozzilli C. Prosperini L, et al. J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):236-8. doi: 10.1136/jnnp-2014-307786. Epub 2014 Apr 30. J Neurol Neurosurg Psychiatry. 2015. PMID: 24790213 No abstract available.

6

Assessment of the effectiveness and safety of natalizumab for treating relapsing-remitting multiple sclerosis.

Fernández-Megía MJ, Casanova B, Magraner MJ, Font-Noguera I, Poveda-Andrés JL. Fernández-Megía MJ, et al. Farm Hosp. 2011 Mar-Apr;35(2):75-9. doi: 10.1016/j.farma.2010.02.003. Epub 2010 Aug 3. Farm Hosp. 2011. PMID: 20685144 Free article. Clinical Trial. English, Spanish.

7

Natalizumab in the treatment of pediatric multiple sclerosis.

Talab R, Talabova M, Klzo L. Talab R, et al. Neuro Endocrinol Lett. 2012;33(6):579-89. Neuro Endocrinol Lett. 2012. PMID: 23160229

8

Immunological markers of optimal response to natalizumab in multiple sclerosis.

Villar LM, García-Sánchez MI, Costa-Frossard L, Espiño M, Roldán E, Páramo D, Lucas M, Izquierdo G, Álvarez-Cermeño JC. Villar LM, et al. Arch Neurol. 2012 Feb;69(2):191-7. doi: 10.1001/archneurol.2011.971. Arch Neurol. 2012. PMID: 22332187

9

Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.

Jander S, Turowski B, Kieseier BC, Hartung HP. Jander S, et al. Mult Scler. 2012 Nov;18(11):1650-2. doi: 10.1177/1352458512463768. Mult Scler. 2012. PMID: 23100527

10

Treating multiple sclerosis with natalizumab.

Iaffaldano P, Lucchese G, Trojano M. Iaffaldano P, et al. Expert Rev Neurother. 2011 Dec;11(12):1683-92. doi: 10.1586/ern.11.154. Expert Rev Neurother. 2011. PMID: 22091593 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

123 results

Results by year